 "Fortis Malar, Lal Path Labs: Diagnostic and healthcare stocks on the charts")
Dr. Lal Path Labs Ltd (LALPATHLAB): The stock is quite stable above the 200-days moving average (DMA) though has not been able to show a strong positive move off-late. The bigger picture illustrates a strong selling pressure above Rs 1,700 levels and is likely to sideways for now, as per the daily chart. The support remains at Rs 1,521, which is its 200-DMA. CLICK HERE FOR THE CHART
Metropolis Healthcare Ltd (METROPOLIS): The daily chart clearly indicates a resistance at 100-DMA located at Rs 1,471 levels. The support remains at 200-DMA, placed at Rs 1,417 levels on a closing basis. If the counter closes below this level, it may slide towards Rs 1,322, which is its 50-DMA. The overall trend may see sellers getting active on a dip below 200-DMA. CLICK HERE FOR THE CHART
Thyrocare Technologies Ltd (THYROCARE): It has been in a consolidation phase from the last two months. On the higher side, Rs 590 has become the resistance, whereas Rs 480 is acting as support on the lower side. The overall trend does not indicate any major rally, as the volume remains subdued. The immediate support is at Rs 500 levels. CLICK HERE FOR THE CHART
Fortis Malar Hospitals Ltd : The stock needs to close decisively above Rs 48 level to show positive upside, as per the weekly chart. Volumes have remained moderate and the price is not showing any exciting moves. The support remains at Rs 40. CLICK HERE FOR THE CHART
Apollo Hospitals Enterprise Ltd (APOLLOHOSP): The downside is capped at the support of 50-DMA, placed at 1,350 levels. The overall trend remasin positive as the Moving Average Convergence Divergence (MACD) is gradually rising above the zero line. The immediate support comes in at Rs 1,390 levels. A rally can take it higher towards Rs 1,440 – Rs 1,450 levels. CLICK HERE FOR THE CHART
Indraprastha Medical Corporation Limited (INDRAMEDCO): The stock is trading near its lifetime high of Rs 66.35 levels. The volumes. too, have increased significantly in the last two sessions. If this counter makes a new lifetime high, then a further upside towards Rs 75 and 80 levels cannot be ruled out. The overall trend remains positive for now. CLICK HERE FOR THE CHART
Metropolis Healthcare Ltd (METROPOLIS): The daily chart clearly indicates a resistance at 100-DMA located at Rs 1,471 levels. The support remains at 200-DMA, placed at Rs 1,417 levels on a closing basis. If the counter closes below this level, it may slide towards Rs 1,322, which is its 50-DMA. The overall trend may see sellers getting active on a dip below 200-DMA. CLICK HERE FOR THE CHART
Thyrocare Technologies Ltd (THYROCARE): It has been in a consolidation phase from the last two months. On the higher side, Rs 590 has become the resistance, whereas Rs 480 is acting as support on the lower side. The overall trend does not indicate any major rally, as the volume remains subdued. The immediate support is at Rs 500 levels. CLICK HERE FOR THE CHART
Fortis Malar Hospitals Ltd : The stock needs to close decisively above Rs 48 level to show positive upside, as per the weekly chart. Volumes have remained moderate and the price is not showing any exciting moves. The support remains at Rs 40. CLICK HERE FOR THE CHART
Apollo Hospitals Enterprise Ltd (APOLLOHOSP): The downside is capped at the support of 50-DMA, placed at 1,350 levels. The overall trend remasin positive as the Moving Average Convergence Divergence (MACD) is gradually rising above the zero line. The immediate support comes in at Rs 1,390 levels. A rally can take it higher towards Rs 1,440 – Rs 1,450 levels. CLICK HERE FOR THE CHART
Indraprastha Medical Corporation Limited (INDRAMEDCO): The stock is trading near its lifetime high of Rs 66.35 levels. The volumes. too, have increased significantly in the last two sessions. If this counter makes a new lifetime high, then a further upside towards Rs 75 and 80 levels cannot be ruled out. The overall trend remains positive for now. CLICK HERE FOR THE CHART
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%